Literature DB >> 7947207

25 years' experience of a gluten-free diet in the treatment of dermatitis herpetiformis.

J J Garioch1, H M Lewis, S A Sargent, J N Leonard, L Fry.   

Abstract

Gluten-free diets have been used in the treatment of patients with dermatitis herpetiformis in our department since 1967. Of the 212 patients with dermatitis herpetiformis attending between 1967 and 1992, 133 managed to take the diet, and 78 of these achieved complete control of their rash by diet alone. Of the remaining 55 patients taking a gluten-free diet, all but three were taking partial diets; over half of these patients managed to substantially reduce the dose of medication required. Of the 77 patients taking a normal diet, eight entered spontaneous remission, giving a remission rate of 10%; a further two patients who had been taking gluten-free diets were found to have remitted when they resumed normal diets. Loss of IgA from the skin was observed in 10 of 41 (24%) patients taking strict gluten-free diets. These patients had been taking their diets for an average of 13 years (range 5-24 years), and their rash had been controlled by diet alone for an average of 10 years (range 3-16 years). The advantages of a gluten-free diet in the management of patients with dermatitis herpetiformis are: (i) the need for medication is reduced or abolished; (ii) there is resolution of the enteropathy, and (iii) patients experience a feeling of well-being after commencing the diet. Thus, we propose that a gluten-free diet is the most appropriate treatment for patients with dermatitis herpetiformis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7947207     DOI: 10.1111/j.1365-2133.1994.tb08557.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  21 in total

1.  Remission in dermatitis herpetiformis: a cohort study.

Authors:  So Yeon Paek; Seth M Steinberg; Stephen I Katz
Journal:  Arch Dermatol       Date:  2010-11-15

2.  A practical approach to treating autoimmune bullous disorders with systemic medications.

Authors:  Anne Han
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

3.  The Oslo definitions for coeliac disease and related terms.

Authors:  Jonas F Ludvigsson; Daniel A Leffler; Julio C Bai; Federico Biagi; Alessio Fasano; Peter H R Green; Marios Hadjivassiliou; Katri Kaukinen; Ciaran P Kelly; Jonathan N Leonard; Knut Erik Aslaksen Lundin; Joseph A Murray; David S Sanders; Marjorie M Walker; Fabiana Zingone; Carolina Ciacci
Journal:  Gut       Date:  2012-02-16       Impact factor: 23.059

4.  Duration of gluten exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders.

Authors:  C Sategna Guidetti; E Solerio; N Scaglione; G Aimo; G Mengozzi
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

Review 5.  [Dermatitis herpetiformis. A clinical chameleon].

Authors:  C Pfeiffer
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

Review 6.  The gluten-free diet and its current application in coeliac disease and dermatitis herpetiformis.

Authors:  Carolina Ciacci; Paul Ciclitira; Marios Hadjivassiliou; Katri Kaukinen; Jonas F Ludvigsson; Norma McGough; David S Sanders; Jeremy Woodward; Jonathan N Leonard; Gillian L Swift
Journal:  United European Gastroenterol J       Date:  2015-04       Impact factor: 4.623

Review 7.  Dapsone in the management of autoimmune bullous diseases.

Authors:  Evan W Piette; Victoria P Werth
Journal:  Dermatol Clin       Date:  2011-10       Impact factor: 3.478

8.  Treatment of subepidermal immunobullous diseases.

Authors:  Donna A Culton; Luis A Diaz
Journal:  Clin Dermatol       Date:  2012 Jan-Feb       Impact factor: 3.541

9.  Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease.

Authors:  P Collin; E Pukkala; T Reunala
Journal:  Gut       Date:  1996-04       Impact factor: 23.059

10.  A new model for dermatitis herpetiformis that uses HLA-DQ8 transgenic NOD mice.

Authors:  Eric Marietta; Kay Black; Michael Camilleri; Patricia Krause; Roy S Rogers; Chella David; Mark R Pittelkow; Joseph A Murray
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.